Genetically Elevated Fetuin-A Levels, Fasting Glucose Levels, and Risk of Type 2 Diabetes

OBJECTIVE Fetuin-A levels are associated with higher risk of type 2 diabetes, but it is unknown if the association is causal. We investigated common (>5%) genetic variants in the fetuin-A gene (AHSG) fetuin-A levels, fasting glucose, and risk of type 2 diabetes. RESEARCH DESIGN AND METHODS Genetic variation, fetuin-A levels, and fasting glucose were assessed in 2,893 Caucasian and 542 African American community-living individuals 65 years of age or older in 1992–1993. RESULTS Common AHSG variants (rs4917 and rs2248690) were strongly associated with fetuin-A concentrations (P < 0.0001). In analyses of 259 incident cases of type 2 diabetes, the single nucleotide polymorphisms (SNPs) were not associated with diabetes risk during follow-up and similar null associations were observed when 579 prevalent cases were included. As expected, higher fetuin-A levels were associated with higher fasting glucose concentrations (1.9 mg/dL [95% CI, 1.2–2.7] higher per SD in Caucasians), but Mendelian randomization analyses using both SNPs as unbiased proxies for measured fetuin-A did not support an association between genetically predicted fetuin-A levels and fasting glucose (−0.3 mg/dL [95% CI, −1.9 to 1.3] lower per SD in Caucasians). The difference between the associations of fasting glucose with actual and genetically predicted fetuin-A level was statistically significant (P = 0.001). Results among the smaller sample of African Americans trended in similar directions but were statistically insignificant. CONCLUSIONS Common variants in the AHSG gene are strongly associated with plasma fetuin-A concentrations, but not with risk of type 2 diabetes or glucose concentrations, raising the possibility that the association between fetuin-A and type 2 diabetes may not be causal.

[1]  Danielle M. Enserro,et al.  Cardiometabolic correlates and heritability of fetuin-A, retinol-binding protein 4, and fatty-acid binding protein 4 in the Framingham Heart Study. , 2012, The Journal of clinical endocrinology and metabolism.

[2]  D. Siscovick,et al.  Association of Fetuin-A With Incident Diabetes Mellitus in Community-Living Older Adults: The Cardiovascular Health Study , 2012, Circulation.

[3]  S. Wild,et al.  Combined Influence of Insulin Resistance, Overweight/Obesity, and Fatty Liver as Risk Factors for Type 2 Diabetes , 2012, Diabetes Care.

[4]  E. Aasheim,et al.  Fetuin A in nonalcoholic fatty liver disease: in vivo and in vitro studies. , 2012, European journal of endocrinology.

[5]  J. Carrero,et al.  Is fetuin-A a mortality risk factor in dialysis patients or a mere risk marker? A Mendelian randomization approach. , 2011, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

[6]  E. Ulukaya,et al.  Serum fetuin A/α2HS-glycoprotein levels in patients with non-alcoholic fatty liver disease: relation with liver fibrosis , 2010, Annals of clinical biochemistry.

[7]  Marcia M. Nizzari,et al.  Candidate Gene Association Resource (CARe): Design, Methods, and Proof of Concept , 2010, Circulation. Cardiovascular genetics.

[8]  Heiner Boeing,et al.  Association of AHSG Gene Polymorphisms With Fetuin-A Plasma Levels and Cardiovascular Diseases in the EPIC-Potsdam Study , 2009, Circulation. Cardiovascular genetics.

[9]  Mark I. McCarthy,et al.  Concept, Design and Implementation of a Cardiovascular Gene-Centric 50 K SNP Array for Large-Scale Genomic Association Studies , 2008, PloS one.

[10]  M. Schulze,et al.  Plasma Fetuin-A Levels and the Risk of Type 2 Diabetes , 2008, Diabetes.

[11]  Annemarie Koster,et al.  Fetuin-A and incident diabetes mellitus in older persons. , 2008, JAMA.

[12]  K. Burgdorf,et al.  AHSG Tag Single Nucleotide Polymorphisms Associate With Type 2 Diabetes and Dyslipidemia , 2008, Diabetes.

[13]  K. Burgdorf,et al.  AHSG tagSNPs associate with type 2 diabetes and dyslipidemia: studies of metabolic traits in 7,683 Danish whites , 2008 .

[14]  Y. Ikeda,et al.  A promoter polymorphism of the α2-HS glycoprotein gene is associated with its transcriptional activity , 2008 .

[15]  Y. Ikeda,et al.  A promoter polymorphism of the alpha2-HS glycoprotein gene is associated with its transcriptional activity. , 2008, Diabetes research and clinical practice.

[16]  P. Froguel,et al.  A synonymous coding polymorphism in the alpha2-Heremans-schmid glycoprotein gene is associated with type 2 diabetes in French Caucasians. , 2005, Diabetes.

[17]  P. Stenvinkel,et al.  Low fetuin-A levels are associated with cardiovascular death: Impact of variations in the gene encoding fetuin. , 2005, Kidney international.

[18]  W. Tian,et al.  Association of α2-HS glycoprotein (AHSG, fetuin-A) polymorphism with AHSG and phosphate serum levels , 2005, Human Genetics.

[19]  Jonathan H. Wright,et al.  A Survey of Weak Instruments and Weak Identification in Generalized Method of Moments , 2002 .

[20]  J. Weber,et al.  Quantitative trait loci on chromosomes 3 and 17 influence phenotypes of the metabolic syndrome. , 2000, Proceedings of the National Academy of Sciences of the United States of America.

[21]  C. Dina,et al.  Genomewide search for type 2 diabetes-susceptibility genes in French whites: evidence for a novel susceptibility locus for early-onset diabetes on chromosome 3q27-qter and independent replication of a type 2-diabetes locus on chromosome 1q21-q24. , 2000, American journal of human genetics.

[22]  G. Grunberger,et al.  Bovine fetuin is an inhibitor of insulin receptor tyrosine kinase. , 1997, Life sciences.

[23]  M. Cushman,et al.  Laboratory methods and quality assurance in the Cardiovascular Health Study. , 1995, Clinical chemistry.

[24]  G. Grunberger,et al.  Serum alpha 2-HS-glycoprotein is an inhibitor of the human insulin receptor at the tyrosine kinase level. , 1993, Molecular endocrinology.

[25]  L. Fried,et al.  Recruitment of adults 65 years and older as participants in the Cardiovascular Health Study. , 1993, Annals of epidemiology.

[26]  P. Savage,et al.  Assessing the use of medications in the elderly: methods and initial experience in the Cardiovascular Health Study. The Cardiovascular Health Study Collaborative Research Group. , 1992, Journal of clinical epidemiology.

[27]  R. Kronmal,et al.  The Cardiovascular Health Study: design and rationale. , 1991, Annals of epidemiology.

[28]  G. Pagès,et al.  Characterization of a natural inhibitor of the insulin receptor tyrosine kinase: cDNA cloning, purification, and anti-mitogenic activity , 1989, Cell.